معرفی
Anna Orlova is a Professor at Uppsala University, holding dual appointments at the Department of Medicinal Chemistry; Theranostics and the Department of Immunology, Genetics and Pathology within the Research Program: Cancer Precision Medicine. Her work focuses on developing novel radiopharmaceuticals for cancer imaging and therapy, with particular expertise in affibody molecules, peptide-based radiotracers, and theranostic approaches for prostate and breast cancer.
Her research spans multiple areas of nuclear medicine and molecular imaging, with emphasis on PSMA, GRPR, and HER2 targeting for cancer diagnostics and therapy. She has pioneered work in affibody-drug conjugates, pretargeting strategies, and optimizing radiolabeling techniques for improved tumor targeting and reduced off-target effects. Her laboratory investigates both diagnostic imaging probes and therapeutic radiopharmaceuticals, often working on theranostic pairs that use the same targeting vector for both diagnosis and treatment.
Dr. Orlova's recent publications demonstrate a strong focus on translating preclinical findings to clinical applications, with multiple first-in-human studies and phase I/II clinical trials. Her work has significantly advanced the field of targeted radionuclide therapy, particularly in optimizing pharmacokinetics through albumin-binding domains and developing novel chelation strategies for improved imaging contrast and therapeutic efficacy.
Her scientific contributions include numerous publications in high-impact journals such as ACS Pharmacology & Translational Science, EJNMMI Radiopharmacy and Chemistry, and Journal of Controlled Release. She collaborates extensively with researchers across Uppsala University and internationally, particularly with Vladimir Tolmachev's research group in the Department of Immunology, Genetics and Pathology.
Dr. Orlova maintains active research programs in multiple areas of cancer theranostics, with ongoing projects focused on improving tumor targeting, reducing hepatic uptake of radiopharmaceuticals, and developing novel therapeutic approaches for cancers with low target expression. Her work bridges basic science with clinical translation, aiming to bring innovative imaging and therapeutic agents to patients with prostate cancer, breast cancer, and other malignancies.
